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To prepare for a possible influenza pandemic, a better
understanding of the potential for the airborne transmission of
influenza from person to person is needed.

Background

The objective of this study was to directly compare the
generation of aerosol particles containing viable influenza virus
during coughs and exhalations.

Objectives

Sixty-one adult volunteer outpatients with influenza-like
symptoms were asked to cough and exhale three times into a
spirometer. Aerosol particles produced during coughing and
exhalation were collected into liquid media using aerosol samplers.
The samples were tested for the presence of viable influenza virus
using a viral replication assay (VRA).

Methods

Fifty-three test subjects tested positive for influenza A
virus. Of these, 28 (53%) produced aerosol particles containing
viable influenza A virus during coughing, and 22 (42%) produced
aerosols with viable virus during exhalation. Thirteen subjects had

Results

both cough aerosol and exhalation aerosol samples that contained
viable virus, 15 had positive cough aerosol samples but negative
exhalation samples, and 9 had positive exhalation samples but
negative cough samples.
Conclusions Viable influenza A virus was detected more often in
cough aerosol particles than in exhalation aerosol particles, but the
difference was not large. Because individuals breathe much more
often than they cough, these results suggest that breathing may
generate more airborne infectious material than coughing over time.
However, both respiratory activities could be important in airborne
influenza transmission. Our results are also consistent with the
theory that much of the aerosol containing viable influenza
originates deep in the lungs.
Keywords Aerosols, air microbiology, airborne transmission,
cough, infectious disease transmission, influenza.

Please cite this paper as: Lindsley et al. (2016) Viable influenza A virus in airborne particles expelled during coughs versus exhalations. Influenza and Other
Respiratory Viruses 10(5), 404–413.

Introduction
During an influenza pandemic, measures to stop the
transmission of influenza virus will be a critical part of
the public health response. Although influenza is known to
be transmitted through respiratory secretions containing the
virus, infectious material can be passed from person to
person in many different ways. The relative importance of
the different pathways is uncertain and probably varies
depending upon the setting, the severity of the illness, the
characteristics of the viral strain, environmental conditions,
and other factors.(1) In order to choose the appropriate
interventions to block the spread of the virus, it is necessary
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to understand which routes of transmission occur and when
they are likely to be important.
The role of airborne transmission in the spread of
influenza has been a question of particular concern to the
public health community while planning for a possible
pandemic.(2,3) If patients can readily infect others via aerosols
(small airborne particles) produced during coughing, speaking, sneezing, and breathing, then interventions such as
patient isolation and cohorting, increased air ventilation and
filtration, air disinfection, and the use of respirators or other
personal protective equipment may help to protect healthcare workers and other patients from the illness. On the other
hand, such interventions can be costly and time-consuming
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and would place additional burdens on healthcare systems
when they are already under considerable strain during a
pandemic. Because of these issues, organizations such as the
Institute of Medicine and the World Health Organization
have called for more research to provide a better understanding of influenza transmission, especially airborne
transmission.(3,4)
Several reports have provided support for the idea that
airborne influenza transmission can occur.(5–8) Influenza
virus RNA has been detected in respirable airborne particles
collected in healthcare facilities and other locations.(9–16)
Influenza virus RNA also has been found in aerosol particles
collected directly from infected patients while they were
coughing and breathing.(17–23) Six studies have demonstrated
that influenza patients expel airborne particles containing
viable virus.(13,18,19,21,24,25) Pantelic et al. found that subjects
with influenza emitted up to 1000 viable influenza virions
over 30 minutes during normal tidal breathing.(25) Lindsley
et al. detected viable influenza A virus in airborne particles
produced during coughing by 7 of 17 influenza patients
(41%).(24) However, even with these reports, the likelihood
of airborne transmission is still unclear, in part because many
questions remain about the production of aerosols carrying
infectious influenza during respiratory activities. For example, no studies have compared the production of virus-laden
airborne particles between different types of respiratory
activities, such as coughing and exhalation. This is an
important question, because the airflow dynamics of coughs
and exhalations are very different. Coughing produces a
high-velocity jet that can propel a plume of aerosol particles
long distances, which disperses the airborne particles
widely.(26) Exhalations have much lower velocities and are
likely to produce higher particle concentrations in the
immediate vicinity of a patient and lower concentrations
further away. Exhalations are also more common than
coughs, which could affect the amount of infectious aerosol
that is generated. These differences could have a significant
impact on disease transmission and on the choice of
interventions.
A comparison of infectious particle production during
coughing and exhaling also would provide clues as to the
sites of origin of influenza-laden particles from within the
respiratory tract. Humans produce more aerosol particles
when they cough vs. when they exhale.(27,28) Most of the
aerosol particles produced during normal breathing are
thought to originate deep in the respiratory tract, while
coughing may produce aerosol both from the lower airways
and also from the upper airways.(29–31) Thus, if coughing
produces much more infectious aerosol than exhaling, this
would suggest that much of the virus in cough-generated
particles may be coming from the upper airways. Conversely,
if the production of infectious aerosol particles during
coughing and exhaling is similar, then that would suggest

that much of the virus-laden aerosol is originating in the
bronchioles and alveoli.
The purpose of this study was to directly compare the
production of aerosol particles containing viable influenza
virus by infected people during coughs and exhalations.
Greater knowledge about the generation of infectious aerosol
particles during different respiratory maneuvers will help to
better understand the likelihood and dynamics of the
possible modes of influenza transmission in different
scenarios and will assist in the selection and evaluation of
interventions to prevent the spread of disease.

Methods
All procedures involving human subjects were reviewed and
approved by the National Institute for Occupational Safety
and Health (NIOSH) and West Virginia University (WVU)
Institutional Review Boards. Written informed consent was
obtained from all study participants.

Aerosol particle collection system
Cough- and exhalation-generated aerosols were collected
using an aerosol particle collection system (Figure 1) similar
to that described previously.(24) An ultrasonic spirometer
(Easy One, NDD Medical Technologies) measured the
volume and flow rate of each cough, and a modified 10liter piston-style mechanical spirometer (SensorMedics
model 762609) served as an accumulation chamber for the
cough and exhalation aerosols. Aerosol particles were
collected using an SKC BioSampler with a 5-ml vessel
(#225-9593, SKC) containing 5 ml of viral transport media
(VTM) consisting of Hank’s balanced salt solution (HBSS;

Patient

Ultrasonic
spirometer Valve
Piston
spirometer

SKC BioSampler
Collection
media
Figure 1. Collection system for airborne particles produced by subjects
during coughing and exhalation. Before each respiratory activity, the
piston spirometer was purged and partially filled with 4 liters of dry
filtered air. The subject then sealed their mouth around the mouthpiece
and coughed or exhaled as instructed. The cough or exhalation traveled
through the ultrasonic spirometer, which measured the volume and flow
rate, and then into the piston spirometer. When the subject was finished,
the valve was closed and the SKC BioSampler was used to collect the
aerosol particles produced by the subject.
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Invitrogen) supplemented with 01% bovine serum albumin
(BSA; Sigma-Aldrich), 100 units/ml penicillin G, and 100
units/ml streptomycin (Invitrogen). The particle collection
efficiency for the SKC BioSampler (i.e., the percentage of
particles of a given size that are collected by the sampler) is
approximately 10% for particles with aerodynamic diameters
of 01 lm; 50% for 03 lm particles; 96% for 1 lm particles;
100% for 2 lm particles; and 50% for 8 lm particles.(32–34)
Particles larger than 10–15 lm are expected to be removed
by the sampler elbow and not collected.

Sample collection procedure
Potential test subjects presenting with influenza-like symptoms at an outpatient clinic were recruited after they had
been seen by their healthcare provider. Potential participants were excluded from the study if they reported
respiratory illnesses such as severe asthma, chronic
obstructive pulmonary disease, or tuberculosis; serious
illnesses such as diabetes or heart disease; pregnancy; or
any condition that would make it difficult or uncomfortable to inhale deeply and cough and exhale forcefully.
After the study was explained to the test subject and
informed consent was obtained, two nasopharyngeal swabs
and an oropharyngeal swab were taken from the subject
and placed in 3 ml of VTM (these will be referred to as
NOP swabs). The subject’s oral temperature was measured
and a brief health questionnaire was administered. The
subject was then asked to sit in front of the aerosol
collection system. The subject was instructed to inhale as
deeply as possible, seal their mouth around the mouthpiece, and cough into the machine using as much of the
air in their lungs as possible. After each cough, the coughgenerated aerosol was collected using the aerosol sampler.
This procedure was repeated for a total of three coughs
from each subject. Next, the subject was asked to repeat
the procedure but to exhale as much and as rapidly as
possible rather than coughing. This was also repeated three
times, and the exhalation-generated aerosol was collected
after each exhalation using the aerosol sampler. The order
of the coughing and exhalation was alternated so that oddnumbered subjects were asked to cough three times
followed by three exhalations, while even-numbered subjects were asked to exhale three times followed by three
coughs. To prevent cross-contamination, the collection
system was purged three times with clean dry air after each
cough or exhalation, and a new mouthpiece was used for
each subject. After the coughs or exhalations were
completed, the VTM were removed from the SKC
BioSampler and placed in a storage tube. All samples in
VTM were kept on ice until the end of the day and then
transported to the laboratory and stored at 80°C until
analysis. Each subject was only asked to perform one test
session.
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Viral replication assay (VRA)
In previous studies of cough and exhalation aerosols by our
group and others, the largest problem has been detecting the
small amounts of viable virus present in these aerosol
samples.(13,18,19,21,24) In this study, a viral replication assay
(VRA) was used to determine whether viable influenza virus
was present in the samples that were collected.(35) The VRA is
more sensitive and easier to use with small sample quantities
than a traditional viral plaque assay or tissue culture
infectious dose assay.(35) In experiments with aerosols
containing viable influenza virus, the VRA amplified the
amount of infectious virus in the samples by a factor of 46 9
105. (35)

Detection of viable influenza virus in NOP swab
samples
For the NOP swab samples, Madin Darby canine kidney
(MDCK) cells (CCL-34) were plated at a density of 50 9 104
per well in a 96-well plate (CoStar 96-well tissue culture
plate, Corning). Triplicate wells were treated with 100 ll of
each sample for 45 minutes. The wells were washed by
adding 100 ll of phosphate-buffered saline (PBS) ml to the
inoculum and removing the resulting supernatant. The cells
were overlaid with 100 ll supplemented Dulbecco’s modified
Eagle’s medium (DMEM)/F12 and incubated for 20 hours at
35°C in a humidified 5% CO2 incubator to allow for viral
replication. Total RNA was isolated from the cells and
supernatant with the MagMaxTM-96 Total RNA Isolation Kit
(Ambion) and transcribed into cDNA using the High
Capacity cDNA Reverse Transcription Kit (Life Technologies). A 5 ll cDNA volume was analyzed using quantitative
PCR (qPCR) with a custom primer/probe set specific for the
matrix (M1) gene or the H3 hemagglutinin gene of influenza
A virus. Details about the primers and probes are provided in
the online supporting information.

Detection of viable influenza virus in cough and
exhalation aerosol samples
For the cough and exhalation aerosol samples, a 6-well
formatted VRA assay was used to increase the sensitivity for
detecting influenza virus in the aerosol samples. MDCK cells
plated at a density of 15 9 106 per well (CoStar 6-well tissue
culture plate, Corning) were incubated at 35°C in a
humidified 5% CO2 incubator overnight. For each sample,
duplicate wells with confluent cellular monolayers were next
washed two times with 2 ml PBS (Invitrogen) and treated
with a 12 ml sample volume for 45 minutes. The wells were
washed by adding 12 ml of PBS to the inoculum and
removing the resulting supernatant. One ml of supplemented
Dulbecco’s modified Eagle’s medium (DMEM)/F12 containing 100 units/ml penicillin G/100 lg/ml streptomycin (Invitrogen), 2 mM L-glutamine (Invitrogen), 02% BSA
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(Sigma-Aldrich), 10 mM HEPES (Invitrogen), 022%
sodium bicarbonate (Invitrogen), 001% DEAE-dextran
(MP BioMedicals, LLC, Solon, OH), and 2 lg/ml N-ptosyl-L-phenylalanine chloromethyl ketone (TPCK) (SigmaAldrich) was added to each well. Treated MDCK cells were
subsequently incubated for 20 hours at 35°C in a humidified
5% CO2 incubator to allow for viral replication. The treated
cellular monolayer was lysed with 1 ml of MagMaxTM Lysis/
Binding Solution Concentrate (Ambion) and the lysate was
pooled with the reserved culture supernatant (final volume of
~ 2 ml) and stored at 80°C until total RNA was isolated.
To account for the larger sample volume in the 6-well
formatted VRA, total RNA was isolated using a modified
MagMaxTM-96 Total RNA Isolation Kit (Ambion) protocol. A
1 ml volume of molecular-grade 2-propanol (Sigma) was
mixed by inversion into each thawed, pooled sample
followed by the addition of 20 ll prepared Bead Mix
(Thermo Scientific). Samples were then gently shaken for
5 minutes and magnetically captured. The supernatant was
discarded and the resulting RNA-bound bead pellet was
resuspended in 150 ll Wash Solution 1 and transferred to a
96-well processing plate. The manufacturer’s instructions
were followed for the remainder of the total RNA isolation
procedure. Total RNA was eluted with 30 ll of elution buffer
and transcribed into cDNA using the High Capacity cDNA
Reverse Transcription Kit (Life Technologies). A 5 ll cDNA
volume was analyzed for the M1 gene using qPCR.

Data analysis
During the qPCR assay portion of the VRA, the samples were
subjected to 45 PCR amplification cycles. The limit of
quantitation (LOQ) of the qPCR assay was 15 viral copies per
PCR tube, which corresponded to a threshold cycle (Ct)
value of 341. The limit of detection (LOD) based on qPCR
only was 10 viral copies per tube, which corresponded to a
threshold cycle (Ct) value of 358. In cases where a PCR
product was detected but the Ct value was higher than the Ct
value for the LOQ, then the PCR product was evaluated by
agarose gel electrophoresis to verify that the PCR product
was the correct size (101 base pairs for the M1 matrix gene).
Sample volumes of 10 ll were loaded into a 45% agarose gel
(Nusieve GTG Agarose, Lonza) along with 10 ll of a 100-bp
DNA ladder (N3231L, New England Biolabs). Electrophoresis was carried out in 1X TAE at 90 volts for approximately
90 minutes. DNA was visualized by ethidium bromide
staining. The LOD with this additional step was as little as
1 viral copy per reaction tube. For additional verification,
DNA sequence analysis was performed on randomly chosen
cough and exhale samples by a commercial laboratory
(Genewiz, Inc.) using pre-defined Sanger DNA sequencing.
Because of the low concentration of influenza virus in the
cough and exhalation aerosol samples, in many cases the
amount of virus detected using the qPCR assay was below the

limit of quantitation for the assay. For this reason, the results
are reported here only as positive or negative for influenza A.
To reduce the possibility of false-positive results, only test
subjects who had NOP swabs that were positive for influenza
by the M1 and H3 gene assays were considered to be
confirmed to have an influenza infection and were used in
the data analysis.
When analyzing the experimental data, a sample was
considered to be positive for influenza if a PCR product
was detected in one or more of the qPCRs and the product
was confirmed to be the correct size by gel electrophoresis.
For example, each cough or exhalation aerosol sample was
tested by inoculating and incubating two culture wells of
MDCK cells, isolating and reverse transcribing the RNA
produced by the cells in each well, and conducting duplicate
qPCR assays for each well. Because of the low amounts of
viable influenza found in the cough and exhalation aerosols,
many of the qPCRs had Ct values that were close to the
maximum limit of 45 cycles for the qPCR assay. For this
reason, if any one of the four qPCRs yielded a PCR product
of the correct size, then that sample was considered influenza
positive even if no PCR product was detected in the other
three reactions. The full results from the qPCR assays are
presented in the supporting information with the online
version of this article.
Statistical analyses included comparison of proportion of
positive coughs and exhalations using McNemar’s test for
paired dichotomous data.(36) The chi-square test was
performed to test for differences in positive cough and
exhalation proportions between the two orders of testing
(cough then exhalation vs. exhalation then cough). All tests
were two-tailed and performed using a 005 significance level.

Results
For this study, 61 adult volunteer subjects were recruited
from college students presenting with influenza-like symptoms at WVU Medicine Student Health Services in Morgantown, West Virginia, USA, during January and February in
2015. A summary of the demographic information, oral
temperatures, cough volume, cough peak flow rate, and
symptoms reported by the test subjects in which viable
influenza A virus was detected is shown in Table 1.
Nasopharyngeal and oropharyngeal (NOP) swabs were
tested for viable influenza A virus using the viral replication
assay (VRA) with qPCR assays for the M1 matrix gene. Fiftythree NOP swab samples (87%) were positive for viable
influenza A. The H3-type hemagglutinin gene was detected
in all 53 samples, consistent with the prevalence of H3N2
influenza A in the United States during the 2014-2015
influenza season. Only test subjects with influenza-positive
NOP swabs were considered to be confirmed to be infected
with influenza and were used in the data analysis.
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Table 1. Demographic and medical information for study
participants confirmed to be infected with influenza. Information for
all of the patients is included in the online supporting information
# Of subjects
Gender
Age (years)
Height (cm)
Weight (kg)
Temperature (°C)
# of days of symptoms
Cough volume (liters)
Peak flow rate during
coughs (liters/second)
Exhalation volume (liters)
Peak flow rate during
exhalation (liters/second)
Number of subjects reporting
Fever/chills
Headache
Fatigue
Cough
Sore throat
Sinus congestion
Runny nose
Sneezing
Muscle aches
Took medication
for symptoms
Received influenza
vaccine
within last 6 months

53
30 Male, 23 Female
Mean
SD
210
34
172
10
766
200
374
07
22
21
27
11
75
22
35
48

10
21

43
40
43
44
41
32
37
28
43
27 yes, 26 no
6 yes, 43 no, 4 unsure

Viable influenza A virus was found in cough aerosol
samples from 28 of 53 subjects and in exhalation aerosol
samples from 22 of 52 subjects confirmed to have influenza
(one exhalation aerosol sample was lost before analysis). The
difference in the number of influenza-positive coughs vs.
influenza-positive exhalations was not statistically significant
(P = 02207). 37 subjects had influenza-positive NOP swabs
and influenza-positive cough or exhalation aerosols, while
for 15 subjects, influenza was detected in the NOP swabs but
not in the cough or exhalation aerosols. Thirteen subjects
had both cough aerosol and exhalation aerosol samples that
contained viable influenza A virus, 15 had positive cough
aerosol samples but negative exhalation samples, 9 had
positive exhalation samples but negative cough samples, and
15 had negative cough and exhalation samples. The order in
which the experiment was performed (coughs followed by
exhalations, or exhalations followed by coughs) did not have
a significant effect on the results (P = 02499). The influenza
results for all test subjects are shown in Table 2.
To confirm that the qPCRs in the VRA were amplifying
influenza virus, the size of the PCR products were verified by
agarose gel electrophoresis. An example electrophoretic gel is

408

Table 2. Presence or absence of viable influenza A virus in NOP
swabs, cough aerosol particles, and exhalation aerosol particles for
each patient. H3 and M1 indicate the influenza A gene that was
targeted in the PCR portion of the VRA

Patient
ID

NOP swab
(M1)

NOP swab
(H3)

Subjects confirmed to have influenza
FC134
+
+
FC135
+
+
FC136
+
+
FC137
+
+
FC138
+
+
FC139
+
+
FC140
+
+
FC141
+
+
FC142
+
+
FC143
+
+
FC144
+
+
FC145
+
+
FC146
+
+
FC150
+
+
FC151
+
+
FC152
+
+
FC153
+
+
FC154
+
+
FC155
+
+
FC157
+
+
FC158
+
+
FC159
+
+
FC160
+
+
FC161
+
+
FC162
+
+
FC163
+
+
FC164
+
+
FC165
+
+
FC166
+
+
FC167
+
+
FC168
+
+
FC171
+
+
FC172
+
+
FC173
+
+
FC174
+
+
FC175
+
+
FC176
+
+
FC177
+
+
FC178
+
+
FC179
+
+
FC180
+
+
FC181
+
+
FC182
+
+
FC183
+
+
FC184
+
+
FC185
+
+
FC186
+
+
FC187
+
+
FC188
+
+
FC190
+
+
FC191
+
+

Cough
(M1)

Exhalation
(M1)

+
+
+

+

+

+
+
+

+

+

+
+

+
+
+

+
+
+
+
+
+
+

+
+

+
+
+
+

+
+
+

+

+
+
+
+
+
+

+
+

+
+
+

+

+

Lost
+
+
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Table 2. (Continued)
Patient
ID

FC192
FC193
Positive
Negative
Total
Subjects not
FC133
FC147
FC148
FC149
FC156
FC169
FC170
FC189

NOP swab
(M1)

NOP swab
(H3)

+
+
+
+
53
53
0
0
53
53
confirmed to have influenza
+

Cough
(M1)

Exhalation
(M1)

+
+
28
25
53

+
22
30
52

+
+

101-base pair bands were observed. The PCR products from
12 H3 gene analyses of the NOP swabs also were tested and
found to be of the correct size (150 base pairs). As additional
verification, the VRA M1 gene PCR products from 7 cough
aerosol samples and 9 exhalation aerosol samples were sent
to a commercial laboratory for sequence analysis. All 7 of the
cough aerosol PCR products and 7 of the 9 exhalation
aerosol PCR products were confirmed to match the matrix
gene segment M1 from influenza A. Two of the exhalation
aerosol PCR products could not be sequenced.

Discussion

+
+
+

shown in Figure 2. A total of 484 qPCRs were performed to
analyze the cough and exhalation aerosol samples from the
61 subjects. Of these, a matrix gene PCR product was
detected in 89 reactions. In 79 reactions (89%), gel
electrophoresis of the PCR product produced a 101-base
pair band, indicating the presence of influenza A. In the
remaining 192 PCRs, a PCR product was not detected and no

Figure 2. Electrophoretic gel used to determine the presence or absence
of a 101-base pair PCR product corresponding to the influenza A M1
matrix gene. The PCR products for the NOP swabs, cough aerosols, and
exhalation aerosols for three test subjects are shown. (+) indicates the
sample is positive for influenza A. ( ) indicates the sample is negative. The
PCR products for the cough and exhalation samples for subject FC178
were confirmed to be from the influenza A M1 matrix gene by DNA
sequence analysis. The negative control contained all PCR reagents,
primers, and probe but no template. The positive control contained
104 M1 copies and was run in parallel with the experimental samples.

Humans infected with influenza virus have been shown to
expel small airborne particles containing viable virus into the
environment when they cough or exhale, which suggests that
the potential exists for the airborne transmission of influenza.(13,18,19,21,24) However, it is not clear how often airborne
transmission actually occurs or what factors affect the
likelihood of transmission by the airborne route, in part
because many questions remain about the processes involved
in infectious aerosol production and the dynamics of these
aerosols in the environment. Consistent with previous
studies, our results show that aerosol particles containing
viable influenza virus are produced by infected individuals
both during coughing and during exhalation. Viable virus
was detected more often in cough aerosol samples (53% of
influenza-positive subjects) compared to exhalation aerosols
(42% of influenza-positive subjects). However, this difference is not substantial and was not statistically significant. As
people breathe constantly but cough sporadically, this
suggests that patients infected with influenza may release
more virus into the air over time in small airborne particles
by breathing compared to coughing. On the other hand, as
coughing involves much higher air velocities than breathing,
coughing may spread the virus further in a given location.
Thus, both mechanisms for producing infectious aerosols
may be important depending upon such factors as the
distance from a patient, the timescale, the infectious dose,
and the air flow within a room.
Viable influenza virus was detected in the cough aerosol,
exhalation aerosol, or both from 37 of 53 influenza-positive
test subjects (70%), which suggests that this is a common
phenomenon. It should be noted that the aerosol collection
system used in these experiments does not capture particles
larger than 10–15 lm in the collection media, and thus
collects only small particles capable of airborne transmission
and not the “large droplets” often referenced in droplet
disease transmission. Viable influenza was detected in both
the cough and exhalation aerosols for 35% of these subjects
(13/37), while it was only detected in the cough aerosol for
41% (15/37) and only in the exhalation aerosol for 24% (9/
37). These results are consistent with somewhat more
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infectious aerosol being released during coughing than
breathing, although they probably also reflect the fact that
the airborne viable virus concentrations are quite low and are
difficult to detect.
Two patients had influenza-positive cough aerosols but
negative NOP swabs, while one had a positive exhalation
aerosol but a negative NOP swab. One possible explanation is
that, because some patients did not tolerate the nasopharyngeal swabs well, the sample obtained may not have been
sufficient for detection of influenza. Alternatively, Milton
et al. (19) reported that the amount of influenza RNA
detected in NOP swabs was only weakly correlated with the
amount detected in exhaled breath; thus, it may be that these
three patients had sufficient influenza virus in their lower
respiratory tract to produce infectious aerosol particles but
insufficient virus in their nasopharyngeal region to be
detected. Finally, the possibility of a false-positive cough or
breath sample or a false-negative NOP swab result cannot be
excluded. For consistency and to reduce the possibility of
false-positive results, only patients with positive NOP swabs
were considered to be confirmed to be infected with
influenza and included in our analysis.
Because of the low concentrations of airborne viable
influenza virus in the cough and exhalation aerosol samples,
we were not able to quantify the amount of airborne viable
virus present in the original samples in our experiments.
However, this should not be interpreted to mean that the risk
of infection is low. Our samples were collected from only
three coughs and three exhalations, while a person infected
with influenza would be expected to cough dozens of times
and breathe hundreds of times per hour and thus could still
release a considerable amount of airborne infectious material
over the course of a day. In addition, the infectious dose for
airborne influenza is very low; one study found that
inhalation of small aerosol particles containing only 07 to
35 plaque-forming units (PFU) of influenza was sufficient to
cause seroconversion in 50% of the human subjects
tested.(37)
The fact that the number of aerosol samples with viable
influenza was not significantly greater for coughing than for
exhalation is consistent with the theory that a substantial
portion of the influenza-laden aerosol produced by infected
people originates in the deepest parts of the lungs rather than
in the upper airways and oropharyngeal region. Smaller
aerosol particles have been proposed to be produced in the
alveolar and bronchial regions during both breathing and
coughing by the formation and rupture of menisci as airways
contract and expand. Larger particles are thought to be
created by shear forces acting on fluid-covered upper
airways, where air velocities are much higher than in the
deeper regions. This phenomenon is thought to occur
primarily during coughing because the air flow rates are
much higher than during breathing.(29–31) Since, in this

410

theory, deep lung particle generation occurs during both
breathing and coughing while upper airway particle generation occurs only during coughing, then the modest increase
in the number of positive samples seen during coughing
compared to exhalation in our experiments supports the idea
that much of the infectious aerosol is originating in the deep
lung regions.
The ability of our system to collect cough and exhalation
aerosols separately was useful for the present study, but it
also significantly limited the study because of the small
amount of aerosol that was collected. By comparison, the
system used by Milton et al. collects aerosols produced by
natural coughs and exhalations over a 30-minute period, and
that group has reported greater success in detecting and
quantifying airborne influenza virus.(19,25,38) Thus, our
results suggest that future work studying infectious aerosol
production and the presence of infectious aerosols in the
environment should collect sample volumes that are as large
as practically possible, which would likely entail using high
sample flow rates and long sample times. Unfortunately,
however, maintaining high flow rates and long sample times
while attempting to collect airborne viruses and maintain
their viability is very challenging, especially when the viruses
are contained in submicrometer aerosol particles.
Finally, it is important to acknowledge the limitations of
our experiments. First, the single most difficult aspect of
studying the production of aerosols containing viable
influenza virus during respiratory activities is the low
concentration of such viruses in the air and the difficulty
in collecting enough material and maintaining viability to
detect the viable virus. To maximize the sensitivity of our
assays and reduce the possibility of false-negative results as
much as possible, the evaluation criteria for our results were
designed to provide the greatest likelihood of detecting small
amounts of viable influenza virus, with steps then taken to
minimize the possibility of false-positive results. However,
we recognize that the possibility of some false-positive
outcomes cannot be ruled out in our analysis.
Second, our test subjects were asked to inhale as deeply as
possible and then cough or exhale using as much of the air in
their lungs as possible. Most natural coughs and normal tidal
breathing use smaller fractions of the total lung capacity,
which may reduce aerosol generation. On the other hand,
natural coughs are stimulated by a need to clear secretions
from the airways, and thus, natural coughs may produce
more aerosol particles than forced coughs. It is also possible
that the ratio of the amount influenza-laden aerosol particles
produced during natural coughing to that produced during
natural breathing may be different than the ratio we found
when comparing forced coughs to forced exhalations.
Third, the particle collection efficiency of the SKC
BioSampler decreases from about 96% for 1 lm aerosol
particles to about 50% for 03 lm particles and 10% for
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01 lm particles.(32–34) Thus, many of the smallest particles
carrying influenza virus may not have been collected in our
experiments. As noted earlier, particles larger than 10–15 lm
were not collected and thus their potential contribution to
disease transmission is not known. In addition, some cough
aerosol particles may have deposited inside the system before
they could be collected. In our previous study using the
cough aerosol collection system,(24) swab samples from the
face of the spirometer piston and the BioSampler elbow
found little influenza, suggesting that particle losses in these
locations were minimal. However, other parts of the system,
such as the mouthpiece, were not tested.
Last, influenza viral shedding peaks around the first day of
acute respiratory illness and then declines rapidly.(19,21,39–41)
In our study, patients presented at the clinic an average of
two days after their symptoms developed (Table 1), well
after the expected maximum in viral shedding. In addition,
our test subjects were college-aged ambulatory outpatients
with no other reported respiratory illnesses or significant
health conditions. Patients who are more severely ill would
generally be expected to have higher viral loads and may be
more likely to produce cough and exhalation aerosols
containing infectious influenza virus, especially in the early
stages of illness.(40,42) Patients who are younger or older,
immunocompromised, or have underlying pulmonary illness
such as asthma or chronic obstructive pulmonary disease also
may have very different infectious aerosol generation
patterns. This could be an important factor during an
influenza pandemic, when healthcare facilities would be
expected to receive large numbers of severely ill patients.

Conclusions
The purpose of this study was to directly compare the expulsion
of aerosol particles containing potentially infectious influenza
virus during coughing and exhalation. Our results confirm that
the production of aerosols containing viable influenza virus is
common among infected people. Viable virus was detected
more often in cough aerosols than in exhalation aerosols, but the
difference was not large. As individuals breathe more often than
they cough, these results suggest that breathing may generate
more airborne infectious material than coughing over time.
However, both respiratory activities could be important in
airborne influenza transmission. Our results are also consistent
with the theory that much of the aerosol containing viable
influenza originates deep in the lungs, although more direct
investigation would be needed to verify this.
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Figure S1. For the direct PCR analysis of the nasopharyngeal and oropharyngeal (NOP) swabs, viral RNA was
extracted directly from 50 µl of each NOP sample.
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